261MO A phase II study of olaparib in patients (pts) with advanced biliary tract cancer (aBTC) with aberrant homologous recombinant repair (HRR) mutations
Titel:
261MO A phase II study of olaparib in patients (pts) with advanced biliary tract cancer (aBTC) with aberrant homologous recombinant repair (HRR) mutations
Auteur:
Ahn, D. Ulrich, A. Park, W. McCue, S. Ou, F-S. Tran, N. Fonkoua, L.A. Kankeu Borad, M.J. Bekaii-Saab, T. Javle, M.